Sun Pharmaceutical Industries on Monday said it has inked a settlement pact with US-based Incyte Corporation regarding Leqselvi, a drug used for severe hair loss.
Under the terms of agreement, the parties will seek dismissal of the pending Leqselvi litigation in the US District Court for the District of New Jersey, and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation, the Mumbai-based drug major said in a statement.
As a part of the agreement, Incyte has granted to Sun a limited, non-exclusive license to US Patent Nos. 9,662,335 and certain other related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications, including alopecia areata, in the US, it added.
Sun will pay Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and license, it stated.
Other specific terms of the settlement and license agreement are confidential, it added.
In a separate statement, the drug firm announced the launch of Leqselvi (8 mg) tablets in the US market.
The medication (deuruxolitinib) is indicated for the treatment of adults with severe alopecia areata.
"The launch of Leqselvi in the US brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them," Richard Ascroft, CEO of Sun Pharma North America, said.
"As a company committed to launching new therapeutic options which address the unmet needs of patients, adding Leqselvi to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community," he added.
Shares of Sun Pharma ended 0.54 per cent higher at Rs 1,681.45 apiece on the BSE.
Under the terms of agreement, the parties will seek dismissal of the pending Leqselvi litigation in the US District Court for the District of New Jersey, and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation, the Mumbai-based drug major said in a statement.
As a part of the agreement, Incyte has granted to Sun a limited, non-exclusive license to US Patent Nos. 9,662,335 and certain other related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications, including alopecia areata, in the US, it added.
Sun will pay Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and license, it stated.
Other specific terms of the settlement and license agreement are confidential, it added.
In a separate statement, the drug firm announced the launch of Leqselvi (8 mg) tablets in the US market.
The medication (deuruxolitinib) is indicated for the treatment of adults with severe alopecia areata.
"The launch of Leqselvi in the US brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them," Richard Ascroft, CEO of Sun Pharma North America, said.
"As a company committed to launching new therapeutic options which address the unmet needs of patients, adding Leqselvi to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community," he added.
Shares of Sun Pharma ended 0.54 per cent higher at Rs 1,681.45 apiece on the BSE.
You may also like
Keir Starmer to have secretive catch-up with Donald Trump during Scotland golfing holiday
Love Island star rushed to medic in unaired moment after injury in villa garden
Sena slapgate heats up: Aaditya Thackeray's 'chhadi-banian gang' swipe sparks Nilesh Rane's dare - 'have guts, take names'
Davina McCall shares bombshell revelation about dying after devastating brain tumour
Sarina Wiegman believes 'urgency' of group stages will help England in Euro 2025 knockouts
